It has been nearly 9years since the FDA (Food and Drug Administration) approved the first
anti-angiogenic drug (bevacizumab) for treatment of metastatic colorectal cancer. Other …

Antiangiogenesis was proposed as a novel target for the treatment of cancer 40 years ago.
Since the original hypothesis put forward by Judah Folkman in 1971, factors that mediate …

Purpose There is no effective therapy for patients with advanced medullary thyroid
carcinoma (MTC). Vandetanib, a once-daily oral inhibitor of RET kinase, vascular …

Kinase inhibitors are now standard treatment for patients with lung cancer whose tumors
harbor specific mutant kinases. Four recent studies, including three in this issue (pages 375 …

Purpose Vandetanib is a once-daily oral inhibitor of vascular endothelial growth factor
receptor, epidermal growth factor receptor (EGFR), and RET signaling. This placebo …

Abstract On April 6, 2011, the US Food and Drug Administration approved vandetanib
(Caprelsa tablets; AstraZeneca Pharmaceuticals LP) for the treatment of symptomatic or …

Distant metastases are the main cause of death in patients with medullary thyroid cancer
(MTC). These 21 recommendations focus on MTC patients with distant metastases and a …

Chronic myeloid leukemia (CML) is caused by the kinase activity of the BCR-Abl fusion
protein. The Abl inhibitors imatinib, nilotinib and dasatinib are currently used to treat CML …

It is now widely accepted that tumor-angiogenesis plays a crucial role in tumor growth, tumor
propagation and metastasis formation. Among several angiogenic activators, the vascular …

Although thyroid cancer usually has an excellent prognosis, few therapeutic options are
available in the refractory setting. Based on the recent results of phase II studies with …